| MBRX Stock | | | USD 2.62 0.03 1.13% |
Moleculin Biotech financial indicator trend analysis is infinitely more than just investigating Moleculin Biotech recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Moleculin Biotech is a good investment. Please check the relationship between Moleculin Biotech Current Deferred Revenue and its Total Assets accounts. Check out
Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in metropolitan statistical area.
For more information on how to buy Moleculin Stock please use our
How to Invest in Moleculin Biotech guide.
Current Deferred Revenue vs Total Assets
Current Deferred Revenue vs Total Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of
Moleculin Biotech Current Deferred Revenue account and
Total Assets. At this time, the significance of the direction appears to have strong relationship.
The correlation between Moleculin Biotech's Current Deferred Revenue and Total Assets is 0.74. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Total Assets in the same time period over historical financial statements of Moleculin Biotech, assuming nothing else is changed. The correlation between historical values of Moleculin Biotech's Current Deferred Revenue and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Moleculin Biotech are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Current Deferred Revenue i.e., Moleculin Biotech's Current Deferred Revenue and Total Assets go up and down completely randomly.
Correlation Coefficient | 0.74 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.
Total Assets
Total assets refers to the total amount of Moleculin Biotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Moleculin Biotech books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.
Most indicators from Moleculin Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Moleculin Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out
Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in metropolitan statistical area.
For more information on how to buy Moleculin Stock please use our
How to Invest in Moleculin Biotech guide.
Selling General Administrative is likely to drop to about 6.9
M in 2024.
Issuance Of Capital Stock is likely to drop to about 200.4
K in 2024
Moleculin Biotech fundamental ratios Correlations
Click cells to compare fundamentals
Moleculin Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Moleculin Biotech fundamental ratios Accounts
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to
measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to
predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.